TOPIC

/ company

Macquarie

The latest news and top stories on Macquarie. A leading entity in the financial services sector, Sydney Australia based Macquarie is a global investment banking and financial services group. They specialise in asset management, retail and business banking, wealth management, and advisory services, serving government institutional corporate and retail clients worldwide. Known as one of the world’s largest infrastructure asset managers and a global specialist in renewables and commodities, Macquarie’s overall business focus is on providing diversified financial solutions. Larry Hu serves as its chief China economist.

A shopping mall in Shanghai. In a bid to avoid economic divergence, China is looking to boost domestic consumption amid weakened domestic demand. Photo: EPA

China consumption

China faces economic balancing act: AI, exports boom while consumers stay home

Two high-level meetings show that Beijing is aware of economic imbalances as Politburo prepares high-stakes growth assessment next month.

30 Jun 2026 - 6:00PM

Fifa

Fifa World Cup tipped to be ‘biggest betting event of all’, with US$50b at stake

26 Jun 2026 - 2:37AM

China’s private sector

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

24 Jun 2026 - 7:00AM

Hong Kong stock market

Lenovo targets US$2b bond to repurchase debt amid AI infrastructure growth

World’s largest PC maker plans to use the proceeds to buy back shares and strengthen its financial position amid sustained growth.

19 Jun 2026 - 7:23PM

Lenovo plans to raise US$2 billion through a convertible-bond offering, according to a filing it made to the Hong Kong stock exchange on Thursday. Photo: Jelly Tse

China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

11 Jun 2026 - 7:52PM

China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

7 Jun 2026 - 7:00PM

Banking & finance

AI | AI infrastructure investment bubble unlikely to burst by 2027: Macquarie

Investors are piling money into AI technologies – but revenues still have a long way to catch up, Macquarie’s Viktor Shvets says.

19 May 2026 - 7:34PM

Google Data Center Southland is seen from the air in Council Bluffs, Iowa, on January 4, 2019. Photos: Reuters

Artificial intelligence

China’s booming tech exports give Beijing ‘wind in its sails’ for Trump summit

The role of tech products in April’s trade data reflects how computing-related goods are a ‘new and important growth driver’ for exports.

12 May 2026 - 11:30PM

Japan

Bound by anxiety: Japan and Australia deepen ties for an uneasy age

Shared concerns about trade coercion and energy shocks are driving the two middle powers to ‘institutionalise’ their partnership.

6 May 2026 - 12:25PM

China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

18 Apr 2026 - 11:05AM

China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

26 Mar 2026 - 11:00AM

Semaglutide generated about US$35 billion in global revenue last year. Photo: AFP

Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

20 Mar 2026 - 2:30PM

US-China trade war

Why Trump pushing China to help reopen the Strait of Hormuz may hurt trade talks

US president’s threat to delay summit with Xi adds uncertainty to Paris negotiations, analysts say.

16 Mar 2026 - 8:30PMvideocam

Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

5 Mar 2026 - 11:01AM

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

4 Mar 2026 - 9:05AM

Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

1 Mar 2026 - 12:00PM

China’s private sector

Lab monkey price tag climbs to US$20,000 thanks to China’s biotech boom

The cost of a single monkey exceeds the average annual salary in China and approaches a pandemic-era spike amid growth in drug licensing deals.

18 Feb 2026 - 8:54PM

Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

13 Jan 2026 - 7:30AM

There were more than 400 million overweight or obese adults in China in 2021, according to a study. Photo: Getty Images

Chinese culture

Language Matters | Word of the Year 2025 choices reflect how virtual our reality has become

From Oxford’s ‘rage bait’ to Macquarie Dictionary’s ‘AI slop’, 2025 WOTYs show the influence of the virtual world on our daily lives.

20 Dec 2025 - 5:15PM

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

20 Dec 2025 - 8:57AM

Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

17 Dec 2025 - 7:30AM

The commercial insurance formulary covers some medicines that are not yet eligible for reimbursement under the country’s National Reimbursement Drug List. Photo: Shutterstock

Hong Kong Monetary Authority (HKMA)

Exclusive | From boardrooms to hiking trails: HKMA courts top bankers with business and leisure

BlackRock’s Larry Fink and General Atlantic’s William Ford will attend the HKMA summit for the first-time.

27 Oct 2025 - 6:27PM

HKMA chief executive Eddie Yue Wai-man plans to show visiting bankers “the real beauty of Hong Kong” during the summit. Photo: Edmond So

US-China trade war

US-China trade flare-up a short-term scare as both sides seek off-ramp: analysts

While US President Donald Trump’s threat of 100 per cent tariffs triggered alarm bells, experts said neither side wants to derail talks.

13 Oct 2025 - 11:25PMvideocam

Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

4 Oct 2025 - 10:56AM

IPO

Chinese healthcare, biotech firms flock to Hong Kong for IPOs

September yields at least 23 listing applications from mainland biotech firms eyeing the city’s lucrative fundraising market.

2 Oct 2025 - 4:30PM

The Hang Seng Biotech index, which tracks the 50 largest biotech, pharmaceutical and medical-device firms listed in Hong Kong, has surged 109 per cent this year. Photo: Shutterstock

Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

26 Sep 2025 - 12:15PM

The Pfizer deal is not good news for Chinese firms developing weight-loss drugs with the aim of reducing injections, an analyst says. Photo: Shutterstock

Banking & finance

After Fed cut, moderate easing expected by China’s central bank, supporting yuan

PBOC sets yuan’s midpoint rate at 7.1085 after first US interest rate cut since December.

18 Sep 2025 - 5:53PMvideocam

India

‘Not desperate’: why India remains firm on US tariff talks as it seeks a deal

The US continues to pressure India to open its agricultural sector after it imposed a 50 per cent tariff on Indian goods.

11 Sep 2025 - 5:00PMvideocam

Help preserve 120 years of quality journalism.

SUPPORT NOW

Macquarie

China faces economic balancing act: AI, exports boom while consumers stay home

Two high-level meetings show that Beijing is aware of economic imbalances as Politburo prepares high-stakes growth assessment next month.

Fifa World Cup tipped to be ‘biggest betting event of all’, with US$50b at stake

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Lenovo targets US$2b bond to repurchase debt amid AI infrastructure growth

World’s largest PC maker plans to use the proceeds to buy back shares and strengthen its financial position amid sustained growth.

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

.css-1f6sr3w{color:#727272;}AI | AI infrastructure investment bubble unlikely to burst by 2027: Macquarie

Investors are piling money into AI technologies – but revenues still have a long way to catch up, Macquarie’s Viktor Shvets says.

China’s booming tech exports give Beijing ‘wind in its sails’ for Trump summit

The role of tech products in April’s trade data reflects how computing-related goods are a ‘new and important growth driver’ for exports.

Bound by anxiety: Japan and Australia deepen ties for an uneasy age

Shared concerns about trade coercion and energy shocks are driving the two middle powers to ‘institutionalise’ their partnership.

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

Why Trump pushing China to help reopen the Strait of Hormuz may hurt trade talks

US president’s threat to delay summit with Xi adds uncertainty to Paris negotiations, analysts say.

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Lab monkey price tag climbs to US$20,000 thanks to China’s biotech boom

The cost of a single monkey exceeds the average annual salary in China and approaches a pandemic-era spike amid growth in drug licensing deals.

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

.css-1pcrwvc{color:#2aa191;}Language Matters | Word of the Year 2025 choices reflect how virtual our reality has become

From Oxford’s ‘rage bait’ to Macquarie Dictionary’s ‘AI slop’, 2025 WOTYs show the influence of the virtual world on our daily lives.

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

Exclusive | From boardrooms to hiking trails: HKMA courts top bankers with business and leisure

BlackRock’s Larry Fink and General Atlantic’s William Ford will attend the HKMA summit for the first-time.

US-China trade flare-up a short-term scare as both sides seek off-ramp: analysts

While US President Donald Trump’s threat of 100 per cent tariffs triggered alarm bells, experts said neither side wants to derail talks.

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

Chinese healthcare, biotech firms flock to Hong Kong for IPOs

September yields at least 23 listing applications from mainland biotech firms eyeing the city’s lucrative fundraising market.

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

After Fed cut, moderate easing expected by China’s central bank, supporting yuan

PBOC sets yuan’s midpoint rate at 7.1085 after first US interest rate cut since December.

‘Not desperate’: why India remains firm on US tariff talks as it seeks a deal

The US continues to pressure India to open its agricultural sector after it imposed a 50 per cent tariff on Indian goods.

AI | AI infrastructure investment bubble unlikely to burst by 2027: Macquarie

Language Matters | Word of the Year 2025 choices reflect how virtual our reality has become